Developer · United States

Delix Therapeutics, Inc.

Private clinical-stage neuroscience company headquartered in Bedford, Massachusetts, developing neuroplastogens — small molecules engineered to produce the rapid structural and functional cortical plasticity associated with psychedelics and ketamine without hallucinogenic, dissociative or sedative effects, so they can be taken at home rather than under supervision. Founded in 2019 by Nick Haft and David E. Olson (UC Davis professor, co-founder and Chief Innovation Officer) on Olson's psychoplastogen discoveries and licensed UC Davis intellectual property. Closed a $70 million Series A in September 2021 led by ARTIS Ventures, RA Capital Management and founding investor OMX Ventures, followed by a $30 million convertible note in January 2022. Lead asset is zalsupindole (DLX-001) in major depressive disorder; the pipeline also includes tabernanthalog (DLX-007), DLX-159 and DLX-2270.

delixtherapeutics.com ↗

1compound
1program
1indication
Phase 1lead asset

Phase distribution

  • Phase 11

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Sep 27, 2021FinancingDelix Therapeutics closes $70 million Series A to advance its neuroplastogen pipelineDelix closed a $70 million Series A led by ARTIS Ventures and RA Capital Management with founding investor OMX Ventures, explicitly to advance two lead candidates through Phase 1 clinical trials and expand the psychoplastogen discovery platform. This is the round that funded DLX-001's move into the clinic; Delix was still preclinical at the time. Followed by a $30 million convertible note financing in January 2022.Zalsupindole (DLX-001)source ↗

Catalysts · 0 upcoming · 2 reported

Recently reported

  • 2025-10-28met

    Zalsupindole (DLX-001)forMajor depressive disorderTopline data

    Phase 1b topline in 18 adults with recurrent MDD: well tolerated with no serious adverse events, no psychotomimetic, hallucinatory or dissociative effects and no acute or persistent cognitive impairment; increased absolute slow-wave delta and theta qEEG power in both cohorts; and approximately 50% MADRS reduction by Day 8 sustained through Day 36 in BOTH the once-daily (7-day) and the intermittent (Days 1 and 4) cohort. Announced together with FDA clearance of the Phase 2 IND including at-home self-administration.

    source ↗

  • 2024-12-12met

    Zalsupindole (DLX-001)forMajor depressive disorderFull results

    Full Phase 1 results for DLX-001 in 106 healthy volunteers, presented at the 2024 ACNP Annual Meeting: no serious adverse events, no psychotomimetic, hallucinatory or dissociative effects at any dose across 2-360 mg oral, dose- and time-dependent resting-state qEEG changes consistent with synaptic strengthening, and measurable cerebrospinal-fluid concentrations confirming CNS penetration at expected therapeutic doses.

    source ↗

Recent activity

  • Oct 28, 2025ReadoutZalsupindole (DLX-001)·Major depressive disordermetPhase 1b topline in 18 adults with recurrent MDD: well tolerated with no serious adverse events, no psychotomimetic, hallucinatory or dissociative effects and no acute or persistent cognitive impairment; increased absolute slow-wave delta and theta qEEG power in both cohorts; and approximately 50% MADRS reduction by Day 8 sustained through Day 36 in BOTH the once-daily (7-day) and the intermittent (Days 1 and 4) cohort. Announced together with FDA clearance of the Phase 2 IND including at-home self-administration.source ↗
  • Dec 12, 2024ReadoutZalsupindole (DLX-001)·Major depressive disordermetFull Phase 1 results for DLX-001 in 106 healthy volunteers, presented at the 2024 ACNP Annual Meeting: no serious adverse events, no psychotomimetic, hallucinatory or dissociative effects at any dose across 2-360 mg oral, dose- and time-dependent resting-state qEEG changes consistent with synaptic strengthening, and measurable cerebrospinal-fluid concentrations confirming CNS penetration at expected therapeutic doses.source ↗
  • Dec 4, 2024Phase changeZalsupindole (DLX-001)·Major depressive disorderPhase 1First MDD PATIENT dosed. Delix announced dosing of the first patient in the Phase 1b trial of DLX-001 in major depressive disorder — approximately 20 patients, evaluating pharmacodynamics (qEEG, polysomnography and exploratory biomarkers), safety, tolerability, pharmacokinetics and preliminary efficacy, dosed daily for seven days at exposures that had produced significant qEEG change in healthy volunteers. Not a phase advance (still Phase 1) but the transition from healthy volunteers to the target patient population, and the point at which this became a patient-stage program. Also unregistered.source ↗
  • May 9, 2023Phase changeZalsupindole (DLX-001)·Major depressive disorderPhase 1First-in-human. Delix announced initiation of the Phase 1 trial of DLX-001 at the Center for Human Drug Research (CHDR) in the Netherlands, planned for approximately 100 healthy volunteers and assessing safety, pharmacokinetics, psychometric function and measures of brain activity/synaptic plasticity. This is the compound's entry into clinical development under the MDD program; it was not registered on ClinicalTrials.gov or any other public registry, so this date comes from the company release rather than a registry record.source ↗

Competitive landscape

Other companies developing against Delix Therapeutics, Inc.'s targets or indications.